Billions of ophthalmology market reshuffle, who will lead the way?

Guide: A text to read eye drug research and development and market pattern!---- in recent years, the eye drug Shapais, which has been brushing on television and on major platforms, has finally been driven out of the "god."reported that shapa-Ess alone, sales in 2016 more than 700 million yuan, accounting for the enterprise's main business revenue of about 70%is theophthalmology market really so profitable? Which drugs are aces in the ophthalmology market? Let's put aside Shapais and look at the real pattern of the current domestic ophthalmic drug marketthe "price war" under the winning strategy consistency evaluation, the domestic generic drug competition is becoming more intense, the introduction of the collection policy, on behalf of the domestic generic generic drug market into the low-margin era, the establishment of the national version of the auxiliary drug catalog, with the gradual introduction of the DRG payment model, will promote hospitals to improve efficiency, save costs, drug structure will also be reshuffledin the face of structural changes in the industry, the future transformation of enterprises mainly has the following three ways: as a domestic Top pharmaceutical company, Hengrui Pharmaceuticals in 2019 high-profile announcement: from the point of view of the ratio of output, has stopped the general generic research projects, only innovative drugs and high-end generic drugs with core valuesbut since then it has again laid out the field of ophthalmology, the introduction of new international dry eye disease drugs, the first to declare his fluoroproscoquine generic drugs, it is known as "small products, large market" reputation of the eye potentialophthalmology drugs: small products, large market "golden ophthalmology, silver surgery" is the medical industry's open secret, indicating that ophthalmology this sub-sector has a huge market valuein recent years, with the aging of the population, people's lifestyle changes and the widespread use of electronic products, the incidence of eye diseases increased, at the same time, people's awareness of eye protection is also increasing, the size of the ophthalmology drug market continues to grow,
,000 percent of china's urban public hospitals sales of ophthalmic drugs were 8.246 billion yuan, up 15.75 percent year-on-year, accounting for 75.44 percent of ophthos in Public Medical Institutions in China, and estimates of 2019 sales of end-of-hospital eye drugs in Public Medical Institutions in China were about 10,930 million yuanif physical and online pharmacies are included, the domestic ophthalmology market is more largethis shows that the domestic ophthalmology market is expandingthe annual sales trend of ophthalmology drugs in Chinese urban public hospitals (units: 10,000 yuan) in the small category pattern, eye vascular disease treatment drugs, dry eye drugs, anti-infective drugs, anti-inflammatory drugs occupy the main market positiondosage pattern, the main dosage forms of ophthalmic drugs are divided into eye preparations, injections, gels, tablets, capsules five categories, eye preparations and injections monopolize the ophthalmology drug TOP10 products the market and competitive situation of the main products, ophthalmological drug varieties list and key varieties of domestic research and development of higher heat eye drops mainly concentrated in dry eye disease, anti-infection, anti-inflammatory, glaucoma and other fields (1) research and development of the hottest products: sodium glass acid sodium osteoleta sodium ophrate for the most widely used clinical artificial tear solution, is also one of the basic drugs of various types of dry eye disease, has become the first sales of eye drops products, in 2019 single-product city public hospital sales of more than 900 million yuan, by the original research and EUSAN occupied the main market based on its excellent market performance, sodium vitate eye drops have become the focus of many ophthalmology enterprises star products, competition is more intense has 3 imports (including original research), 16 domestic products, of which 2 (Chengdu Push Pharmaceuticals and Jiangxi Cherish Ming) for the new 4 categories approved, that is, as the same through the consistency evaluation in addition, there are four (Zhongshan Wanhan Pharmaceuticals, Yangzijiang Pharmaceuticals, Shenyang Xingqi, Shandong Haishan) have submitted listing applications, is currently in the process of review and approval But for strong domestic enterprises, there is still a chance to break the market and reshape the market (2) Other products with higher research and development in addition to sodium gagenta, other products with higher attention are polyethylene alcohol, olothadin, moxisac, zooxyfluoratin, quproproprosin, latanprosin, aflate prosthestandin and atropine sulfate detailed market and competition as follows: (3) another way, can pay attention to the cold products in recent years, China's market Praofin, tubin, Malayic acid? focus on the development of cold products, can avoid fierce competition, is expected to achieve the first imitation of the listing or the first through consistency evaluation, to seize the market opportunity sales and competition for less competitive pressure eye drops are as follows: Notes: Sales data source: Micin database - China's urban public hospitals BE test exemption regulations require eye preparations are usually used in a local way of administration, generally no systemic absorption, and therefore established for the evaluation of oral solid formulations drug bioetic ionics in vivopharmaceutical research methods are not applicable to eye preparations from the current situation, play a local role of the real solution can be exempted from BE research, thereby greatly accelerating the progress of research and development, reduce research and development costs other eye preparations need to be analyzed according to the condition of the variety can focus on the project summary ophthalmology drugs belong to the specialized field, consistency evaluation progress is slow overall, the competitive pressure is small, in the process of DRG payment and consistency evaluation, the therapeutic value of the chemical drug market will be further expanded, is expected to be high-quality drugs into the future fierce competition recommendations can focus on the project: 1 Consistency evaluation project left oxyfluorosacin eye drops tubopenodo omelet eye drops Malay acid 2 New 4 items sodium glass acid drop eye drops ground quarphos sodium eye drops olotate dislocated eye drops hydrochloride nitrogen zostin ochost eye drops taxmo Sdyd eye drops Pralovin eye drops sodium brominate dropane ostrich hydrochloride moxisa star eye drops ratensin restoconprosic reflux reflux eye drops eye drops 3 New 3 items litaster eye drops naepafenamine eye drops polyethylene alcohol eye drops.